18 May 2023 in Clinical Genitourinary Cancer
14 November 2024 in American Journal of Neuroradiology
BACKGROUND AND PURPOSE: To develop and evaluate an automated, AI-based, volumetric brain tumor MRI response assessment algorithm on a large cohort of patients treated at a high-volume brain tumor center. MATERIALS AND METHODS: We retrospectively analyzed data from 634 patients treated for glioblastoma at a single brain tumor center over a 5-year period (2017-2021). The mean age was 56 +/-13 years. 372/634 (59%) patients were male, and 262/634 (41%) patients were female. Study data consisted of 3,403 brain MRI exams and corresponding standardized, radiologist-based brain tumor response assessments (BT-RADS). An artificial intelligence (AI)-based brain tumor response assessment algorithm was developed using automated, volumetric tumor segmentation. AI-based response assessments were evaluated for agreement with radiologist-based response assessments and ability to stratify patients by overall survival. Metrics were computed to assess the agreement using BTRADS as the ground-truth, fixed-time point survival analysis was conducted to evaluate the survival stratification, and associated P-values were calculated. RESULTS: For all BT-RADS categories, AI-based response assessments showed moderate agreement with radiologists’ response assessments (F1 = 0.587-0.755). Kaplan-Meier survival analysis revealed statistically worse overall fixed time point survival for patients assessed as image worsening equivalent to RANO progression by human alone compared to by AI alone (log-rank P=0.007). Cox proportional hazard model analysis showed a disadvantage to AI-based assessments for overall survival prediction (P=0.012). CONCLUSIONS: AI-based volumetric glioblastoma MRI response assessment following BT-RADS criteria yielded moderate agreement for replicating human response assessments and slightly worse stratification by overall survival. ABBREVIATIONS: GBM= Glioblastoma; RANO= Response Assessment in Neuro-Oncology; BTRADS= Brain Tumor Reporting and Data System; NLP = Natural Language Processing.
21 October 2026 in Radiology: Artificial Intelligence
The Brain Tumor Reporting and Data System (BT-RADS) standardizes posttreatment MRI response assessment in patients with diffuse gliomas but requires complex integration of imaging trends, medication effects, and radiation timing. An end-to-end multiagent large language model and convolutional neural network system for automated BTRADS classification was developed and evaluated. Five hundred nine consecutive posttreatment glioma MRI examinations (March 2017-July 2021) from a single center were retrospectively evaluated. An extractor agent identified clinical variables from notes using gpt-oss (OpenAI, 20-billion parameters). A scorer agent applied BTRADS decision logic integrating these with quantitative volumetrics. System accuracy was compared against initial assessments, using expert annotation as the reference standard. Four hundred ninety-two examinations were evaluable. Overall system accuracy was 76.0% (374/492) versus 57.5% (283/492) for initial assessments, an absolute difference of +18.5 percentage points ( P < .001). Cohen kappa between the system and the reference standard was 0.71. The system achieved high sensitivity in context-dependent categories (BT-1b; 100%; BT-1a, 92.7%; BT-3a, 87.5%) and moderate sensitivity for threshold-dependent categories (BT-3c, 74.8%; BT-2, 69.2%; BT-4, 69.3%; BT-3b, 57.1%). The BT-4 positive predictive value was 92.9%. These results support further evaluation of this system as a clinical decision-support tool, with local open-weight inference preserving data privacy. ©RSNA, 2026